| dc.contributor.author | Ribera, Josep-María | |
| dc.contributor.author | Garcia, Olga | |
| dc.contributor.author | Grande, Carlos | |
| dc.contributor.author | Esteve, Jordi | |
| dc.contributor.author | Oriol, Albert | |
| dc.contributor.author | Bergua, Juan | |
| dc.contributor.author | González-Campos, José | |
| dc.contributor.author | Vall-Llovera, Ferrán | |
| dc.contributor.author | Tormo, Mar | |
| dc.contributor.author | Hernandez-Rivas, Jesus María | |
| dc.contributor.author | García, Daniel | |
| dc.contributor.author | Brunet, Salut | |
| dc.contributor.author | Alonso, Natalia | |
| dc.contributor.author | Barba, Pere | |
| dc.contributor.author | Miralles, Pilar | |
| dc.contributor.author | Llorente, Andreu | |
| dc.contributor.author | Montesinos, Pau | |
| dc.contributor.author | Moreno, María-José | |
| dc.contributor.author | Hernandez-Rivas, Jose Angel | |
| dc.contributor.author | Bernal, Teresa | |
| dc.date.accessioned | 2025-01-31T07:34:02Z | |
| dc.date.available | 2025-01-31T07:34:02Z | |
| dc.date.issued | 2013-05-01 | |
| dc.identifier.citation | Cancer, 119(9), p. 1660-1668 (2013); doi:10.1002/cncr.27918 | |
| dc.identifier.uri | https://hdl.handle.net/10651/76404 | |
| dc.description.sponsorship | Supported in part by the grant RD12-0036-0029 from
RTICC Instituto Carlos III, Spain. | |
| dc.format.extent | p. 1660-1668 | spa |
| dc.language.iso | spa | spa |
| dc.relation.ispartof | Cancer 119(9) | spa |
| dc.rights | © 2013 American Cancer Society | |
| dc.title | Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab) | spa |
| dc.type | journal article | spa |
| dc.identifier.doi | 10.1002/cncr.27918 | |
| dc.relation.projectID | RD12-0036-0029 | |
| dc.relation.publisherversion | https://doi.org/10.1002/cncr.27918 | |
| dc.rights.accessRights | embargoed access | |
| dc.type.hasVersion | VoR | |
